retatrutide triple agonist Retatrutide: The first-in-class investigational receptor redefining Type 2 diabetes therapy Retatrutide, a triple agonist, delivered
Pay in 4 interest-free payments of $6.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13




























